{"id":8173,"date":"2021-06-04T15:28:33","date_gmt":"2021-06-04T15:28:33","guid":{"rendered":"https:\/\/amarintech.com\/?p=8173"},"modified":"2021-06-04T15:28:33","modified_gmt":"2021-06-04T15:28:33","slug":"opportunities-in-an-evolving-market","status":"publish","type":"post","link":"https:\/\/amarintech.com\/es\/opportunities-in-an-evolving-market\/","title":{"rendered":"Opportunities in an evolving market"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t
\n\t\t\t\n\t\n\t\n\t\n<\/svg>\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t

Opportunities in
an evolving market <\/h1>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

By Germ\u00e1n M\u00fcller \u2013 Business Development Manager<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Introduction<\/b><\/p>

In a first and superficial approach to the main market indicators, and in line with some publications, we can have feeling of witnessing the twilight of one the most innovative pharmaceutical forms in the industry, however, there are still several business opportunities for those who know how to identify them.<\/p>

My objective for this article is to introduce the reader to these opportunities through the analysis of global and regional trends in the transdermal market, from the beginning, and with a focus on the last decade.<\/p>

I will undertake the evaluation essentially from a numerical perspective regarding the market niche for transdermal products, circumscribing my assessment to the market for transdermal patches, intentionally excluding the market for \u201cplasters\u201d (which is about half the size of patches). Briefly, we can summarize that the main difference between is that transdermal patches have a systemic effect on the body, while plasters are limited to a local action at the site of application (according on the explained in \u201cTopical and transdermal\u201d<\/span><\/a>)<\/p>

\u00a0<\/p>

The beginnings\u00a0<\/span><\/b><\/p>

The first product to be launched to the market was a patch with reservoir technology programmed to release 1.5 mg of Scpolamine within three days (Transderm Scop\u00ae; Novartis Consumer Health). The product was launched in 1979 in the United States, and its therapeutic indication was the prevention of nausea and vomiting caused by motion sickness.<\/p>

Forty years after its launch, and despite the fact that this technology has made great advances, Scopolamine patches not only continue to be present on the market, but they still hold the title of remaining within the top ten of best selling molecules in this pharmaceutical form.<\/p>

It is important to mention that the APIs (Active Pharmaceutical Ingredient) that can be administered transdermally are limited, essentially due to a variety of technical complexities. For this reason, and considering the growing number of inexperienced players entering the industry as I will detail later, it is crucial to make partnerships with companies with a long history in transdermals if you want to access this niche, since they will substantially improve the chances of being successful.<\/p>

From that first launch to the present, about 20 molecules have been approved by the FDA to be administered systemically by the transdermal route, achieving the boom of this pharmaceutical form with respect to the number of launches, towards the mid-2000s. A detailed list of innovative products approved by the FDA is listed below:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Global trend<\/b><\/p>

On below chart it can be perceived that, according to the behavior of its main variables, the global transdermal market could be entering its maturity stage, given the drop in the turnover along with a less pronounced decline in the volume of sold units:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

It stands out in this comprehensive view, a first decline in billing between 2005 and 2006, which was motivated by the entry of generic Fentanyl patches. Then the sales continued to rise until reaching its peak in 2014 exceeding USD 6B, promoted by the historical highs of both the Estradiol patch and the Exelon\u00ae (Rivastigmine patch).<\/p>

Since then, a systematic decrease in both turnover and volume has been observed, which was mainly justified in two aspects:<\/p>